Home > Topoisomerase & > Voreloxin

Voreloxin

Vosaroxin,SNS-595,SNS 595,SNS595, AG 7352

Voreloxin能抑制拓扑异构酶II，有抗肿瘤活性。

目录号
EY0558
EY0558
EY0558
EY0558
纯度
99.58%
99.58%
99.58%
99.58%
规格
1 mg
5 mg
10 mg
50 mg
原价
620
1300
2200
4500
售价
620
1300
2200
4500
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Voreloxin is a potent Topoisomerase II inhibitor with broad-spectrum anti-tumor activity. Phase 2.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

    ~10 微克/毫升

  • 动物实验

    ~50 mg/kg 腹腔注射

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Tsuzuki Y, et al. J Med Chem. 2004, 47(8), 2097-2109.
    [2] Advani, Ranjana H.; Hurwitz, Herbert I.; Gordon, Michael S. et al. Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules. Clinical Cancer Research (2010), 16(7), 2167-2175.
    [3] Scatena, Caroline D.; Kumer, Jeffrey L.; Arbitrario, Jennifer P. et al. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo. Cancer Chemotherapy and Pharmacology (2010), 66(5), 881-888.
    [4] Abbas JA, Stuart RK. Vosaroxin : a novel antineoplastic quinolone. Expert Opin Investig Drugs. 2012 Aug;21(8):1223-33.

    分子式
    C18H19N5O4S    		 分子量
    401.44    		 CAS号
    175414-77-4    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    10 mM    		 Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT00541866 Acute Myeloid Leukemia Drug: voreloxin injection and cytarabine Sunesis Pharmaceuticals Phase 1|Phase 2 2007-08-01 2012-06-05
    NCT00607997 Leukemia|Acute Disease|Acute Myeloid Leukemia|Nonlymphocytic Leukemia|Myelodysplastic Syndromes Drug: voreloxin Sunesis Pharmaceuticals Phase 2 2008-04-01 2012-06-05
    NCT00408603 Epithelial Ovarian Cancer Drug: Voreloxin Injection Sunesis Pharmaceuticals Phase 2 2006-11-01 2012-06-05
    NCT01913951 Myelodysplastic Syndromes Drug: vosaroxin|Drug: Azacitidine Washington University School of Medicine Phase 1 2013-11-22 2017-02-18
    NCT01980056 Myelodysplastic Syndrome Drug: Vosaroxin Weill Medical College of Cornell University|Sunesis Pharmaceuticals Phase 1|Phase 2 2013-10-25 2017-03-01
    NCT00246662 Leukemia, Lymphocytic, Acute|Leukemia, Nonlymphocytic, Acute|Leukemia, Myeloid, Chronic|Myelodysplastic Syndromes Drug: Vosaroxin Sunesis Pharmaceuticals Phase 1 2005-11-01 2017-02-06
    NCT02658487 Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Acute Myeloid Leukemia With Multilineage Dysplasia|Myeloid Sarcoma|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Therapy-Related Myelodysplastic Syndrome Drug: Cytarabine|Drug: Vosaroxin Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) Phase 2 2016-03-01 2016-10-06
    NCT01893320 Leukemia Drug: Vosaroxin|Drug: Decitabine M.D. Anderson Cancer Center|Sunesis Pharmaceuticals Phase 1|Phase 2 2013-07-18 2017-02-03
    NCT01191801 Leukemia|Acute Myeloid Leukemia|Acute Nonlymphocytic Leukemia Drug: vosaroxin and cytarabine|Drug: placebo and cytarabine Sunesis Pharmaceuticals Phase 3 2010-10-01 2013-10-10
    NCT02485353 Leukemia, Myeloid, Acute Drug: Vosaroxin and Cytarabine Hamid Sayar|Indiana University 2015-10-01 2016-08-24
    NCT00091585 Neoplasms Drug: SNS-595 Sunesis Pharmaceuticals Phase 1 2004-06-01 2007-05-09
    NCT00094159 Neoplasms Drug: SNS-595 Sunesis Pharmaceuticals Phase 1 2004-10-01 2007-05-09
    NCT00298896 Carcinoma, Small Cell|Small Cell Lung Cancer Drug: SNS-595 Injection Sunesis Pharmaceuticals Phase 2 2006-02-01 2009-03-05
    NCT00252382 Carcinoma, Non-Small-Cell Lung Drug: SNS-595 Injection Sunesis Pharmaceuticals Phase 2 2005-11-01 2007-05-09

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：